ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how effective and safe LY2157299, in combination with
chemotherapy and radiation therapy, might be in treating rectal cancer. Also as part of this
study, research will be done on tumor samples to see if it is possible to predict if patients
will respond to treatment, and blood samples to look at the immune system response to study
treatment.
About 50 people will take part in this study. The study treatment will be given over an 8
week period and the investigators will continue to collect your health information for up to
5 years, as part of this study